What's Going to Be Hot at AHA 2023
Buzz is building for SELECT, the semaglutide CV outcomes trial, and ORBITA-2, a sham-controlled trial of PCI in stable CAD.
Stay updated with breaking news from Todd Neale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Buzz is building for SELECT, the semaglutide CV outcomes trial, and ORBITA-2, a sham-controlled trial of PCI in stable CAD.
Several FDA alerts made the list this month, but our biggest stories focused on MOC gripes and new chronic CAD guidelines.
Three features won awards in the Media/Publications category, and an Off Script piece picked up a Blog Post prize.
A Novavax decision in the US, wasted vaccine doses, soaring global seroprevalence, Paxlovid’s impact, sniffer dogs, and more.
Memorial day infections, South African reinfections, booster doses against Omicron, global CV “collateral damage,” and more.